139 related articles for article (PubMed ID: 38789608)
21. Semaglutide and Cardiovascular Outcomes.
Taqueti VR; Shaw LJ
N Engl J Med; 2024 Feb; 390(8):766. PubMed ID: 38381682
[No Abstract] [Full Text] [Related]
22. Research digest: pioneering an oral GLP-1 receptor agonist.
Atkinson MA; Powers AC
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):897. PubMed ID: 31748168
[No Abstract] [Full Text] [Related]
23. Effect of glucagon-like peptide-1 receptor agonists in subjects with type 2 diabetes mellitus: A meta-analysis.
Qian W; Liu F; Yang Q
J Clin Pharm Ther; 2021 Dec; 46(6):1650-1658. PubMed ID: 34355405
[TBL] [Abstract][Full Text] [Related]
24. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
Torekov SS
Cardiovasc Res; 2018 Aug; 114(10):e70-e71. PubMed ID: 30052921
[No Abstract] [Full Text] [Related]
25. Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective.
Sidik S
Nature; 2023 Jul; 619(7968):19. PubMed ID: 37369789
[No Abstract] [Full Text] [Related]
26. Generalizability of results from the recent FDA-guided cardiovascular outcomes trials to a representative population with Type 2 Diabetes attending primary care clinics.
Vinagre I; Gerstein H; Viñals C; Conget I
Endocrinol Diabetes Nutr (Engl Ed); 2019; 66(7):467-468. PubMed ID: 30890422
[No Abstract] [Full Text] [Related]
27. Semaglutide 2.4 mg: the latest GLP-1RA approved for obesity.
Villela R; Correa R
J Investig Med; 2022 Jan; 70(1):3-4. PubMed ID: 34949728
[No Abstract] [Full Text] [Related]
28. Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials.
Mellbin LG; Bhatt DL; David JP; Ekström K; Petrie MC; Rasmussen S; Vilsbøll T
Eur Heart J; 2024 Apr; 45(15):1371-1374. PubMed ID: 38416593
[No Abstract] [Full Text] [Related]
29. Semaglutide (Ozempic)--another injectable GLP-1 receptor agonist for type 2 diabetes.
Med Lett Drugs Ther; 2018 Jan; 60(1539):19-21. PubMed ID: 29364197
[No Abstract] [Full Text] [Related]
30. At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide.
Ruder K
JAMA; 2024 Jan; 331(1):9-11. PubMed ID: 38055301
[TBL] [Abstract][Full Text] [Related]
31. The kidney and cardiovascular outcome trials.
Bloomgarden Z
J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
[TBL] [Abstract][Full Text] [Related]
32. Once-Weekly Semaglutide Is an Effective Adjunct for Weight Loss in Adults without Diabetes Who Are Overweight or Obese.
Slawson DC
Am Fam Physician; 2021 Jul; 104(1):96-97. PubMed ID: 34264618
[No Abstract] [Full Text] [Related]
33. Semaglutide Improved Cardiovascular Health in People Without Diabetes.
Harris E
JAMA; 2023 Dec; 330(23):2241-2242. PubMed ID: 38019508
[No Abstract] [Full Text] [Related]
34. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
35. Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes.
Goldenberg RM; Steen O
Can J Diabetes; 2019 Mar; 43(2):136-145. PubMed ID: 30195966
[TBL] [Abstract][Full Text] [Related]
36. Review: metformin: potential benefits and use in chronic kidney disease.
Pilmore HL
Nephrology (Carlton); 2010 Jun; 15(4):412-8. PubMed ID: 20609092
[TBL] [Abstract][Full Text] [Related]
37. Safety of Semaglutide.
Smits MM; Van Raalte DH
Front Endocrinol (Lausanne); 2021; 12():645563. PubMed ID: 34305810
[TBL] [Abstract][Full Text] [Related]
38. Eligibility for and Preventive Potential of Semaglutide in Overweight and Obese Patients With Myocardial Infarction.
Hansen MK; Olesen KKW; Gyldenkerne C; Thrane PG; Stødkilde-Jørgensen N; Mortensen MB; Maeng M
J Am Coll Cardiol; 2024 Mar; 83(9):956-958. PubMed ID: 38418010
[No Abstract] [Full Text] [Related]
39. Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?
Kim HS; Jung CH
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576096
[TBL] [Abstract][Full Text] [Related]
40. The SELECT trial of semaglutide in patients with overweight or obesity without diabetes: establishing a new pathway to secondary prevention of cardiovascular disease.
Lincoff AM; Ryan DH
Eur Heart J Cardiovasc Pharmacother; 2024 Feb; 10(2):93-94. PubMed ID: 38066700
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
